The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people with lymphoma have this type, and it mainly affects older adults. It’s a fast ...

Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma and mantle cell lymphoma. Roche’s heritage in non-hodgkin lymphoma treatment Rituximab ...

Diffuse large B cell lymphoma (DLBCL) is cancer involving B cells. Under the microscope, the cells look just like the cancerous T cells found in anaplastic large cell lymphoma (ALCL). Both of ...

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy cemacabtagene ansegedleucel (cema-cel; Allogene ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

A research team led by Prof. Gu Hongcang from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...